Treatment Action Group Applauds Progress on Ending HIV in New York, Cautions Against Complacency
TAG Stands with Safehouse and Opposes Dangerous Policies That Jeopardize Access to Lifesaving Harm Reduction Services
TAG Comment in Response to Proposed Rulemaking: Visas: Ineligibility Based on Public Charge Grounds
Statement: Truly Corrective Actions on Drug Pricing Will Bring Life-Saving Benefit to Consumers in the U.S. and Globally
This is a joint statement from TAG and Health GAP October 16, 2019 – Although Speaker Nancy Pelosi’s bill to increase affordable access to medicines in the U.S., H.R. 3, offers halting, partial steps to reduce drug prices for some…
ANEA Response to Guardian Article on Gov. Rick Scott’s Rejection of $70 Million in Federal Funding to Fight Florida’s HIV/AIDS Crisis
Ensuring Treatment for Children with Orphan Diseases: Ending Exemptions from the Pediatric Research Equity Act (PREA)
August 27, 2019 – This policy brief was developed by TAG and the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), and it details how children with TB are affected by the pediatric research exemption for orphan drugs. The brief also proposes…
Pharma Lies, People Die: Myth-Busting Fact Sheet on Medicine Development and Pricing
By Bryn Gay, HCV Project Director, TAG and Claudine Guerra, CUNY DOWNLOAD to print this article as a poster (A1 size) The current leaders of the United States manufacture crises, media optics, and catchy sound bites to side step actual…
Getting Rid of the Boogeyman: The Reality of Prescription Drug Price Controls
By Annette Gaudino, HCV/HIV Project Co-Director, TAG Do you remember how old you were when you stopped believing in the monster under your bed? How many times did you have to look and see nothing there before you finally believed…
Fierce Activism from the Global Access to Medicines (A2M) Movement: Reflections on Recent Sucess
By Bryn Gay, HCV Project Director, TAG Access to medicines (A2M) activists have become better coordinated, articulate, and adept in responding to pharmaceutical industry shenanigans that threaten access to affordable medicines since the establishment of harmonized global intellectual property (IP) …